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AKTThe p21-activated kinase (PAK) family of serine/threonine kinases plays an important role in cell
proliferation, survival and motility, as well as in cell transformation and tumor progression. PAK1 promotes
transformation through facilitating the ERK/MAPK pathway and enhances cell migration and survival by
stimulating AKT. PAK1 expression increases with the progression of colorectal cancer (CRC). In this study, we
have investigated the importance of PAK1 in the biology of colon cancer cells. Reduction of PAK1 expression
decreased the activities of ERK and AKT leading to decreased cell proliferation, migration/invasion, and
survival. Dual inhibition of ERK and AKT suppressed these cellular processes to levels comparable to those
achieved by reduction of PAK1 expression, whereas inactivation of either the ERK or AKT pathway alone
partially inhibited cell migration/invasion and survival and had no effect on proliferation. We conclude that
PAK1 stimulates colon cancer cell proliferation, migration/invasion, and survival via ERK- and AKT-
dependent pathways. These ﬁndings establish the central importance of PAK1 in CRC signal transduction and
clarify the mechanism by which PAK1 regulates CRC growth and migration. Instead of simultaneously
inhibiting both ERK and AKT, the PAK1 convergence point could be an alternative target for CRC therapy.olorectal carcinoma or cancer;
activated kinase/ERK kinase;
atidylinositol 3-kinase; VEGF,
iversity of Melbourne, Austin
. Fax: +61 3 9458 1650.
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Colorectal cancer (CRC) develops through multiple processes
involving progressive disruption of cell proliferation, differentiation,
and survival [1]. Mutations in KRas and BRaf have been found in 40%
and 10% of CRC, respectively [2,3]. KRas and BRaf activate the
mitogen-activated protein kinase (MAPK)/extracellular signal-regu-
lated kinase (ERK) [3] cascade. The fact that overexpression and
activation of MAPK and ERK play important roles in the progression of
CRC makes MAPK and ERK potential molecular targets for CRC
treatment, although clinical trials of appropriate inhibitors to date
have been disappointing [4]. Alternatively, KRas stimulates the
phosphatidylinositol 3-kinase (PI3K)/AKT-dependent pathway [5].
Mutations in PI3K occur in 30% of epithelial cancers [6], and 22% of
CRC harbour mutations in both KRas and PI3K [7,8]. The recent
discovery that activation of the PI3K pathway contributes to the
resistance to MAPK kinase (MEK) inhibitors in CRC cells [9,10]
suggests that therapy with a combination of PI3K and MEK inhibitors
may be a more effective treatment for cancers having mutations inKRas and PI3K, as has already been demonstrated in animal models of
lung cancer [11].
p21-activated kinase 1 (PAK1), a downstream effector of Rac and
Cdc42, is a key player in cellular mechanisms important for
transformation and tumor progression. PAK1 is essential for malignant
transformation induced by Ras, Rac, and Cdc42, placing PAK1 at a
convergence point in transformation induced by small GTPases. PAK1
enhances transformation through the ERK/MAPK pathway [12], and
activated PAK1 stimulates theproliferation and anchorage-independent
growth of mammary epithelial cancer cells [13]. PAK1 is also required
forVEGFexpression inhumanbreast cancer cell lines and, consequently,
for angiogenesis,which, in turn, promotes tumor growth andmetastasis
[14]. In CRC, PAK1 expression was found to increase with progression
through the adenoma to carcinoma sequence, with the most dramatic
increases in invasive and metastatic CRC [15]. PAK1 phosphorylates Raf
and MEK and facilitates the Ras/Raf/MAPK signalling pathway in COS
ﬁbroblasts [16,17] and hence could play an important role in CRC
development. Recently, PAK1has been found to stimulate cellmigration
and survival by activating AKT in cardiomyocytes and in COS ﬁbroblasts
[18,19]. Since Ras activates PAK1 via PI3K-dependent or independent
pathways [20], and mutations in Ras and PI3K play important roles in
CRC, it is possible that PAK1 functions as a convergence point receiving
signals from Ras and PI3K and stimulates CRC to grow and migrate by
activation of AKT and ERK.
The aim of this study was to deﬁne the role of PAK1 in CRC cell
growth, migration/invasion, and survival. We ﬁrst investigated the
effect on these processes of a reduction in PAK1 expression in the
1107N. Huynh et al. / Biochimica et Biophysica Acta 1803 (2010) 1106–1113human CRC cell lines DLD1 and HCT 116 by stable transfection with
plasmids encoding PAK1 shRNA. The role of ERK and AKT in the
stimulation of these cellular processes by PAK1 was also investigated
by treatment with the selective inhibitors U0126 and LY294002,
respectively. Finally, the same inhibitors were used to study the
requirement for ERK and AKT in the stimulation of VEGF production
by PAK1.
2. Materials and methods
2.1. Reagents, cell culture, and shRNA transfection
SureSilencing shRNA plasmids for human PAK1 were purchased
from SABioscience (Frederick, MD, USA). The MEK inhibitor U0126
and antibodies against phospho-PAK1, PAK1, phospho-ERK1/2,
ERK1/2, phospho-AKT, AKT, and GAPDH were purchased from Cell
Signalling Technology (Genesearch, Melbourne, Australia). The
human VEGF ELISA kit was purchased from R&D systems (Minnea-
polis, MN, USA). The PI3K inhibitor LY294002 was purchased from
Sigma (Sydney, Australia).
The human colon cancer cell lines DLD1 and HCT 116 were
obtained from ATCC, were negative in a mycoplasma test, and were
cultured in RPMI medium containing 5% FBS. To obtain PAK1 knock-
down cells, DLD1 or HCT 116 cells were transfected with plasmid
DNAs encoding shRNA sequences to silence the PAK1 gene speciﬁcally
or with a scrambled sequence as a negative control using Lipofectin
Reagent (Invitrogen, Melbourne, Australia) according to the manufac-
turer's instructions. Stable cloneswere selectedwith G418 (1 mg/ml).
PAK1 protein expression was detected by Western blot.
2.2. Cell proliferation and survival assay
Cell proliferation was assayed by 3H-thymidine incorporation and
cell count. Cells were seeded in a 96-well plate at a density of 5×103Fig. 1. PAK1 is required for colon cancer cell proliferation and migration/invasion. Proliferati
signiﬁcantly reduced in PAK1 knock-down (KD) cells when compared with negative control (
and migration/invasion by Boyden chamber assay as described in Materials and methods. T
raw data (B), represent data summarised from three independent sets of experiments. *pbcells/well in RPMI containing 5% FBS and 10 μCi/ml [methyl-3H]-
thymidine plus or minus U0126 (10 μM) and/or LY294002 (10 μM)
for 24 h or 48 h and then harvested using a NUNC cell harvester. The
amount of 3H-thymidine incorporated through DNA synthesis was
detected with a β-counter (Packard, Meriden, CT). For cell counting,
the cells were counted in a haemocytometer after culturing for the
indicated times.
To determine cell survival, cells were seeded in a 96-well plate at
3–5×103 cells/well in RPMI containing 5% FBS and 10 μCi/ml
[methyl-3H]-thymidine, and cultured for 20 h. The medium contain-
ing free unincorporated 3H-thymidine was then removed. Cells were
washed twicewith PBS and culturedwith orwithout serum for a further
48 h in the absence or presence of U0126 (10 μM) and/or LY294002
(10 μM). The cellswereharvested, and the 3H-thymidine remaining from
that incorporated in the ﬁrst 20 h was detected as described above. Cell
survivalwasmeasured as the ratio of the 3H-thymidine incorporated into
DNA after the different treatments to the value for the serum control.
2.3. Cell migration/invasion assay
Cell migration/invasion was determined using the Boyden
Chamber assay described by Ishizu et al. [21] with the following
modiﬁcations. Membranes (8-μm pore size, Becton Dickinson, NJ,
USA) were coated with 3 μg of human ﬁbronectin on the lower
surfaces and placed into a 24-well plate containing 600 μl/well of
serum-free RPMI with 0.1% BSA. Cells (2–5×104/100 μl/chamber)
were added to the upper chambers and incubated for 24 h at 37°C in a
5% CO2 atmosphere plus or minus U0126 and/or LY294002. The cells
on the upper surface of themembranes were removed by wiping with
a cotton swab before the membranes were ﬁxed and stained with
Quick-Dip (Fronine, Sydney, Australia). The cells that had migrated to
the lower surface of themembranes were counted from 24 ﬁelds at 40
times the magniﬁcation using a NIKON Coolscope (Coherent Scien-
tiﬁc, Adelaide, Australia).on (A, B) and migration/invasion (C, D) of DLD1 (A, C) or HCT116 (B, D) cells were both
NC) cells. Proliferation was measured by 3H-thymidine incorporation and cell counting,
he results, expressed as a percentage of the value obtained for NC cells (A, C, and D), or
0.05, **pb0.01 compared to NC13 (A, C), NC7 (B), or average of NC7 and 8 (D).
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Cells were cultured in 10-mm dishes or 6-well plates in RPMI
without serum for 24 h in the absence or presence of U0126 (10 μM)
and/or LY294002 (10 μM). Themediawere then collected and cleared
by centrifugation, and the VEGF concentrations were determined
using a VEGF ELISA kit (R&D systems, Minneapolis, MN, USA) follow-
ing the manufacturer's instruction. The concentrations of VEGF fromFig. 2. PAK1 knock-down inhibited activities of ERK and AKT. PAK1 expression was signiﬁcan
(NC) cells byWestern blot (A). The PAK1 levels were expressed relative to the average densit
in PAK1 KD DLD1 cells. Both PAK1 KD and NC cells were treated with or without the PI3K in
serum for 24 h. The activities of ERK and AKT were determined by the amounts of phosphor
and IS cells run in parallel on the same gels. The ratios of phosphorylated ERK (pERK) or AKT
results represent data summarized from three independent sets of experiments. ***pb0.001
IS2.23 (A). *pb0.05, **pb0.01, compared to the values obtained from untreated NC cells (Bthe culture media were assayed in duplicate at a 1:4 dilution and
corrected for total cell numbers.
2.5. Immunoblotting
Cells were lysed in lysis buffer (50 mMHEPES, pH 7.5, 150 mMNaCl,
5 mMMgCl2, 1% NP40, 1 mMDTT, 5 μg/ml aprotinin, 5 μg/ml leupeptin,
and 1 mM PMSF). The cell lysates were centrifuged at 12,000 rpm fortly reduced in DLD1 PAK1 knock-down cells (IS) when compared with negative control
y for NC13 and NC14 taken as 1 (A). Activities of ERK (B, C) and AKT (D, E) were reduced
hibitor LY294002 (Ly, 10 μM) or the MEK inhibitor U0126 (U, 10 μM) in the presence of
ylated ERK and AKT detected in cell lysates by Western blots, with lysates from both NC
(pAKT) to total ERK (tERK) or AKT (tAKT) from untreated NC cells were taken as 1. The
compared to the average value obtained from NC13 and NC14 (A). ##pb0.001 IS2.11 vs
–E).
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natants was quantiﬁed using Bradford reagent (Sigma). The proteins in
the supernatants were resolved by SDS–PAGE and detected with anti-
bodies against phospho-ERK1/2, ERK1/2, phospho-AKT, ATK, PAK1, and
GAPDH. Bound antibodies were visualized using ECL reagents (GE
Healthcare, Buckinghamshire, UK), and the density of each band was
analysed using Multigauge computer software (Berthold, Bundoora,
Australia).
2.6. Statistical analysis
All values are expressed as means±standard error. Results were
analyzed by one-way analysis of variance. If there was a statistically
signiﬁcant difference in the data set, individual values were compared by
Bonferroni's t test with the unstimulated control, or with the values
obtained in the presence of MEK and PI3K inhibitors as appropriate.
Differences between twomeanswith pb0.05were considered signiﬁcant.
3. Results
3.1. PAK1 is required for colon cancer cell proliferation and migration/
invasion
To determine the role of PAK1 in colon cancer cell proliferation and
migration/invasion, the human colon cancer cell lines DLD1 and
HCT116 (both of which bear mutations in Ras and PI3K) [9,10] were
transfected with plasmid DNAs containing either shRNA insert
sequences to knock-down PAK1 or scrambled sequences to serve as
a negative control (NC). Among four insert sequences provided by the
manufacturer (SABioscience, Frederick, MD, USA), PAK1 knock-down
(KD) clones were successfully selected from cells transfected with
insert sequences 2 (IS2) and 3 (IS3) (Supplementary Fig. 1). The
selected PAK1 KD clones had PAK1 protein expression less than 10% of
value in the NC cells transfected with scrambled sequences. Both
PAK1 KD and NC cells were then subjected to proliferation and
migration/invasion assays as described inMaterials andmethods. Cell
proliferation was signiﬁcantly decreased in PAK1 KD DLD1 cells by
24 h and 48 h (Fig. 1A). The maximum decrement was over 80% in
clones IS2.5 and IS2.23 after 48 h of culture. Similarly, the PAK1 KD
HCT116 cells grew signiﬁcantly more slowly than the NC cells
(Fig. 1B), with the maximum decrement over 75% by 96 h of culture.
Compared with NC cells, PAK1 KD cells migrated signiﬁcantly more
slowly in a Boyden chamber assay. The numbers of PAK1 KD cells that
penetrated through the membrane were reduced to at least 50%
(DLD1; Fig. 1C) or 30% (HCT116; Fig. 1D) of the numbers of NC cells.
These results indicate that PAK1 is required for colon cancer cell
proliferation and migration/invasion.Fig. 3. PAK1 stimulated proliferation and migration/invasion via ERK- and AKT-dependent pat
inMaterials andmethods. DLD1 cells were treatedwith or without LY294002 (Ly, 10 μM) and/
The results represent data summarized from three independent sets of experiments. *pb0.05
compared between NC and PAK KD cells.3.2. PAK1 stimulates proliferation and migration/invasion via ERK- and
AKT-dependent pathways
Since PAK1promotes the Ras/Raf/MAPK/ERK signalling pathwayby
phosphorylation of Raf and MEK [12] and enhances cell migration and
survival by activation of AKT [18,19], it is possible that PAK1 regulates
cell proliferation and migration/invasion by activation of ERK and AKT
in these colon cancer cells, which bear mutations in both Ras and PI3K.
To investigate this possibility, the activities of ERK and AKT were
determined in both negative control (NC13 and NC14) and PAK1 KD
(IS2.11 and IS2.23) DLD1 cells. PAK1 expression by IS2.11 and IS2.23
cellswas reduced to 10%and5%of the average PAK1expressionbyNC13
and NC14 cells, respectively (Fig. 2A). In PAK1 KD cells, the activity of
ERK (measured as the ratio of phosphorylated ERK to total ERK) was
signiﬁcantly reduced to 40–60% of the value in NC cells (Figs. 2B and C).
The activity of AKT (the ratio of phosphorylated AKT to total AKT) in
PAK1 KD cells was also decreased to 30–50% of the activity in NC cells
(Figs. 2D and E). In NC cells, inhibition of MEK by U0126 or of PI3K by
LY294002 decreased the levels of phosphorylated ERK or AKT,
respectively, to their levels in PAK1 KD cells (Figs. 2B–E), while no
further inhibition of ERKorAKTactivitieswasobserved inPAK1KDcells.
The involvement of ERK- and AKT-dependent pathways in prolifer-
ation and migration/invasion was further investigated with the MEK
inhibitor (U0126) and/or with the PI3K inhibitor (LY294002). Both
inhibitors were tested at a concentration of 10μMon the basis of data in
the literature [22–25] and studies of dosedependency (data not shown).
TheproliferationofNC cellswas signiﬁcantly andmaximally inhibited in
the presence of both MEK and PI3K inhibitors, while neither of them
alone signiﬁcantly inhibited the proliferation of NC cells (Figs. 3A andB).
These inhibitors had no effect on the proliferation of PAK1 KD cells, as
was observed with ERK and AKT activities. In the migration/invasion
assay, inhibition of MEK by U0126 reduced the migration of NC cells to
80% of untreated cells, while inhibition of PI3K by LY294002 had no
effect on migration/invasion (Fig. 3C). However, simultaneous inhibi-
tion of both MEK and PI3K maximally decreased the migration of NC
cells to the value observed in PAK1 KD cells (Fig. 3C), while neither
inhibitorhad a signiﬁcant effect on themigrationof PAK1KDcells. These
results indicate that both ERK and AKT activities are required for colon
cancer cell proliferation and migration/invasion, that ERK- and AKT-
dependent pathways compensate for each other in mediating prolifer-
ation and migration, and that PAK1 knock-down blocks proliferation
and migration/invasion through inactivation of ERK and AKT.
3.3. PAK1 promotes colon cancer cell survival via ERK and AKT pathways
The effect of PAK1 on cell survival in the absence of serum was
determined as described in Materials and methods. Serum withdrawalhways. Cell proliferation (A, B) and migration/invasion (C) were determined as described
or U0126 (U, 10 μM). The values obtained from the untreated NC cells were taken as 100%.
, **pb0.01, with comparisons as indicated in the ﬁgures; #pb0.05, ##pb0.01, with values
Fig. 4. PAK1 promoted cell survival via ERK- and AKT-dependent pathways. DLD1 cells were incubatedwith 3H-thymidine in serum [8] for 20 h, washed to remove free 3H-thymidine,
and cultured for 48 h with or without serum (A) plus or minus LY294002 (Ly, 10 μM) and/or U0126 (U, 10 μM) (B–D). The residual 3H-thymidine incorporated into DNA was
quantitated as described in theMaterials andmethods and taken as ameasure of cell survival. The values obtained in cells culturedwith serumwere taken as 100%. Survival of PAK1KD
cells, but not NC cells, was signiﬁcantly reduced in the absence of serum (A). Cell survival in NC cells in the absence of serum was signiﬁcantly reduced in the presence of U0126
(U, 10 μM) and/or LY294002 (Ly, 10 μM) (B, C). There was no further reduction in survival of PAK1 KD cells in the presence of U0126 and LY294002 (D). The results represent data
summarized from three independent sets of experiments. *pb0.05, **pb0.01, comparedwith the cells culturedwith serum (A, B, C) or, with comparisons as indicated in the ﬁgure (D).
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approximately 40% of PAK1 KD cells died after 48 h of serum-free
culture (Fig. 4A). To determine the effects of ERK and AKT on cell
survival in the absence of serum, cells were cultured with or without
U0126 and/or LY294002 for 48 h. The NC cells treated with either
U0126or LY294002 alone showedsigniﬁcant cell death compared to the
cells cultured in serum (Figs. 4B and C). The cell survival rates in the
presence of either U0126 or LY294002 alone were reduced to 70–80%,
and in the presence of both inhibitors to 60%, of the valueobserved inNC
cells grown in the presence of serum (Figs. 4B and C). The reduced
survival rates of NC cells in the presence of both inhibitors were
comparable to those of PAK1KD cells, and the cell survival rates of PAK1
KD cells were not affected by U0126 and LY294002 (Fig. 4D). TheseFig. 5. PAK1 enhanced VEGF production via ERK- and AKT-dependent pathways. DLD1 cells w
LY294002 (Ly, 10 μM). The VEGF concentrations inmedia weremeasured by ELISA as describ
experiments, with VEGF production from untransfected wild type (WT) DLD1 cells (A) or un
(A) or with comparisons as indicated in the ﬁgure (B, C).results indicate that PAK1 is essential for colon cancer cell survival, and
that PAK1promotes cell survival byERK-andAKT-dependentpathways.
3.4. PAK1 enhances VEGF secretion via ERK and AKT pathways
In CRC, vascular endothelial growth factor (VEGF) expression
correlates with cancer stage and prognosis [26–29]. VEGF stimulates
angiogenesis, which further promotes tumor survival and migration.
VEGF production from PAK1 KD cells, measured by ELISA, was
signiﬁcantly lower than from wild type and NC cells (Fig. 5A). By 24 h
of culture, VEGF production was reduced by more than 50% in PAK1
KD cells. VEGF production by NC cells was signiﬁcantly inhibited by
U0126 alone and decreased to a greater extent by LY294002 alone orere cultured in serum-free medium for 24 h with or without U0126 (U, 10 μM) and/or
ed inMaterials andmethods. Results represent themean values from three independent
treated NC13 (B) or NC14 (C) cells taken as 100%. *pb0.05, **pb0.01 compared withWT
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by the PAK1 KD clone IS2.23 was not affected by U0126 and/or
LY294002. The production of VEGF by the PAK1 KD clone IS2.11 wasFig. 6. Inhibition of the ERK activity induced by serum withdrawal increased AKT activity.
measured in extracts of DLD1 NC and PAK1 KD (IS) cells cultured with or without serum [8] f
NC and IS cells run in parallel on the same gels. Serum withdrawal increased pERK in NC ce
serum from either PAK1 KD or NC cells (C, D). Inhibition of MEK with U0126 (10 μM) blocke
absence of serum to a level similar to the level in the presence of serum (F). The results repre
(tERK) or total AKT (tAKT). * and #pb0.05, ** and ##pb0.01 compared to the values obtainnot affected by U0126 but reduced slightly and signiﬁcantly by
LY294002 (Figs. 5B and C). The difference between the two clones
could be due to the residual amount of PAK1 expressed in IS2.11 cellsPhosphorylated ERK (pERK) (A, B, E) and phosphorylated AKT (pAKT) (C, D, F) were
or 48 h byWestern blots as described in Materials and methods, with lysates from both
lls, but not in PAK1 KD cells (A, B). pAKT was dramatically decreased by withdrawing
d the increment in pERK induced by serum withdrawal (E), but stimulated pAKT in the
sent data from three independent experiments and are expressed as a ratio to total ERK
with serum or with comparisons as indicated in the ﬁgure.
Fig. 7. PAK1 mediates cell proliferation, survival, and migration/invasion through both
ERK- and AKT-dependent pathways. PAK1 is activated by Ras via PI3K-dependent and
independent pathways. PAK1 then activates ERK and AKT, and activation leads to
increased cell proliferation, survival, and migration/invasion. U0126 and LY294002 are
selective inhibitors of MEK and PI3K, respectively. Inhibition of PAK1 by an as yet
unidentiﬁed compound X may be more effective than simultaneous inhibition of both
ERK and AKT. PDK: 3-phosphoinositide-dependent protein kinase.
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production and that PAK1 enhances VEGF production via ERK- and
AKT-dependent pathways.
3.5. ERK and AKT compensate for each other in PAK1-stimulated cell
proliferation, migration/invasion, and survival
In the presence of serum, PAK1 knock-down reduced the activities
of ERK and AKT (Fig. 2), leading to decreased proliferation and
migration/invasion (Fig. 1). In the absence of serum, ERK activity
signiﬁcantly increased in NC cells, but not in PAK1 KD cells (Figs. 6A
and B), while AKT activity decreased in both PAK1 KD and NC cells
(Figs. 6C and D). The increased activity of ERK in the absence of serum,
together with the reduced but critical AKT activity, protected cells
from death and contributed to VEGF secretion. Interestingly, in the
absence of serum, inhibition of ERK activity by U0126 (Fig. 6E)
increased the activity of AKT in NC cells (Fig. 6F) and the increase in
AKT activity may promote cell survival and VEGF production despite
the inhibited ERK activity. These results suggest that ERK and AKT
compensate for each other in PAK1-stimulated cell proliferation,
migration/invasion, and survival.
4. Discussion
The biological consequences of increased PAK1 signalling in
human cancers have been explored extensively in breast cancers
and neuroﬁbromatosis [20] but less well studied in colorectal cancers.
In particular, the role of PAK1 in CRC growth and metastasis has
not been investigated before. Our ﬁndings that inhibition of PAK1
suppressed CRC cell proliferation, survival, migration/invasion, and
VEGF production indicate the multiple roles and importance of PAK1
in CRC growth and metastasis.
In agreement with previous reports [9,10], our observation that
cell proliferation, survival, and migration/invasion are maximally
decreased by simultaneous inhibition of both ERK and AKT indicates
that both ERK- and AKT-dependent pathways are required for these
cellular processes. In addition, the observation that dual inhibition of
ERK and AKT decreased cell survival, VEGF production, andmigration/
invasion to levels similar to those achieved by blocking PAK1 alone
indicates that PAK1 stimulates these cellular processes by activation
of both ERK and AKT. However, the fact that the decrement of cell
proliferation caused by blocking PAK1 alone is greater than the
decrement caused by dual inhibition of ERK and AKT suggested that
other pathway(s) in addition to ERK and AKT may be involved in
PAK1-mediated cell proliferation.
Reduction of PAK1 expression decreased the activities of ERK and
AKT and decreased cell proliferation, migration/invasion, survival, and
VEGF production. The observation that PAK1 knock-down inhibited the
activities of both ERK and AKT identiﬁes PAK1 as a convergence point
common to both the Ras/Raf/ERK- and PI3K/AKT-dependent signalling
pathways. About 30% of human tumors have signs of MAPK pathway
activation represented by high phosphorylation levels of ERK1/2 [30].
Deregulation of this pathway in cancers occursmost frequently through
activating mutations in KRas and BRaf. KRas also stimulates the PI3K/
AKT pathway [5], which is vital to cancer cell growth and survival.
Mutations in PI3K occur in 30% of epithelial cancers including CRC [6]. A
recent discovery has indicated that the MAPK/ERK and PI3K/AKT
pathways can compensate for each other in the stimulation of cancer
growth andmigration [9,10]. The prediction that combination therapies
of PI3K and MEK inhibitors may be more effective than either inhibitor
on its own for cancerswithmutations in KRas and PI3Khas already been
veriﬁed in a murine lung cancer model [11]. In this study, we have
shown that PAK1 is essential for the activation of both ERK and AKT
pathways, which are required for stimulation of CRC cell growth and
migration/invasion. Since PAK1 is activated by Ras through both PI3K-
dependent and -independent pathways [20], PAK1 may act as aconvergence point for transmitting signals from Ras and PI3K by
activating downstream ERK and AKT pathways leading to cell
proliferation, survival, and migration/invasion. Instead of targeting
both MAPK/ERK and PI3K/AKT, targeting PAK1 alone could be equally
effective in treating cancers with mutations in Ras and PI3K.
In conclusion, our study supports a model (Fig. 7) in which PAK1,
activated by Ras and PI3K, transmits the signal further by activation of
ERK- and AKT-dependent pathways leading ultimately to increased
cell proliferation, survival, and migration/invasion. PAK1 may act as a
convergence point in transformation induced by Ras and PI3K and
hence may serve as a more effective target in CRC therapy than
simultaneous inhibition of both PI3K/AKT and MEK/ERK.
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